149. Effect of Lurasidone on Quality of Life, Function, and Metabolic Parameters in Adolescent Patients With Schizophrenia: Results From a 6-Week, Double-Blind, Placebo-Controlled Study

Background: Several atypical antipsychotics are approved to treat adolescent patients with schizophrenia. However, risk for antipsychotic-associated weight gain and metabolic dysfunction underscores the need to identify additional evidence-based treatments that are both efficacious and well tolerate...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Schizophr Bull
Hlavní autoři: Findling, Robert, Goldman, Robert, Cucchiaro, Josephine, Deng, Ling, Loebel, Antony
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475665/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbx021.207
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky